Tag Archives: ATRA

Top 10 Performing Stocks To Buy For 2018

March 16, 2017: Markets opened higher again Thursday but the uptick did not last longer. Within an hour shares had dropped and a brief turn higher was foiled quickly. The worst performing sectors for the day are utilities and healthcare, with financials showing the only decent gain. WTI crude oil for April delivery settled at $48.75 a barrel, down 0.2% on the day. April gold added 2.2% on the day to settle at $1,227.10. Equities were headed for a lower close shortly before the bell as the DJIA traded down 0.11% for the day, the S&P 500 traded down 0.22%, and the Nasdaq Composite traded down 0.02%.

The DJIA stock posting the largest daily percentage loss ahead of the close Thursday was E.I. du Pont de Nemours Inc. (NYSE: DD) which traded down 1.14% at $80.56. The stock’s 52-week range is $61.12 to $81.51. Volume was roughly 40% below the daily average of around 2.6 million shares. The company had no specific news.

Chevron Corp. (NYSE: CVX) traded down 1.00% at $107.79. The stock’s 52-week range is $92.25 to $119.00. Volume was about 10% below the daily average of around 6.3 million shares. The integrated oil & gas company had no specific news.

Top 10 Performing Stocks To Buy For 2018: Tobira Therapeutics, Inc.(TBRA)

Advisors’ Opinion:

  • [By Benzinga News Desk]

    Allergan (NYSE: AGN) acquired Akarna Therapeutics global rights to AKN-083 for up-front payment of $50 million. This came just hours after Allergan bought Tobira Therapeutics (NASDAQ: TBRA) for upfront Payment of $28.35 share in cash, up to $49.84 per share in CVRs.

Top 10 Performing Stocks To Buy For 2018: TESARO, Inc.(TSRO)

Advisors’ Opinion:

  • [By George Budwell]

    Unfortunately for Clovis and its shareholders, though, Astra’s Lynparza is currently underpriority review with the FDA as a maintenance therapy in ovarian cancer, andTesaro’s (NASDAQ:TSRO)rival PARP inhibitor Zejula gained an early approval– along with afar broader label than Rubraca — just this week.

  • [By Ben Levisohn]

    Who has PARP? A poly ADP-ribose polymerase inhibitor (PARPi) kills cancer cells by interfering tumor DNA repair pathway with the potential to treat ovarian, breast and prostate cancer. Studies have shown that patients with BRCA mutations (BRCAmut) respond to PARPi. AstraZenecas (AZN) PARPi was approved in 2014 whileClovis Oncology (CLVS) and Tesaro (TSRO) both have positive Phase III data. Clovis licensed its PARPi from Pfizer (PFE) in 2011 and Tesaro licensed its PARPi from Merck (MRK) in 2012, after Sanofis (SNY) PARPi (later demonstrated that it cannot block PARP) failed in Phase III in early 2011.

  • [By Todd Campbell]

    The PARP battle is on. Following news that AstraZeneca’s (NYSE:AZN) PARP-inhibiting cancer drug Lynparza delivered a big win in phase 3 studies, all eyes now shift to how a potential Food and Drug Administration approval for Lynparza will reshape the commercial opportunity for competitor Tesaro Inc. (NASDAQ:TSRO).

  • [By Ben Levisohn]

    Shares of Tesaro (TSRO) are soaring today after the biotech company reported positive data for its treatment of ovarian cancer over the weekend. Credit Suisse analyst Alethia Young and team contend that “M&A remains in focus” for Tesaro following the data:

    Getty Images

    We are increasing our target price to $122 from $90 as we move to an M&A DCF valuation. We were at ESMO this weekend, and we believe the big takeaway on Tesaro data is that it works broadly in all 2L ovarian populations and safety looks solid. We also think the robustness of this data bodes well from PRIMA and QUADRA but are maintaining our POS here. We have looked at our model and also adjusted durations in first-line. We think Tesaro remains one of the most attractive and de-risked cancer assets in our landscape and the company has been cited in major press sources as a takeout target (Bloomberg, Investor Business Daily).

    We think M&A remains in focus for Tesaro. Our M&A DCF valuations range from $122 to $157 by our model. We have also built models for other cancers like NSCLC, SCLC, prostate, and others where PARP might be impactful. We assume 0% POS for now but we conservatively see at least another $1B in sales from PARP expansion. Tesaro has been cited in the press as a potential M&A target and is a company we frequently hear mentioned as a target from our conversations. We think the demand for late stage oncology assets is high, especially in the PARP space given the potential for activity across a range of tumors. For a large Pharma player who already has an oncology salesforce and large R&D infrastructure we could see SG&A synergies of 50-75% and R&D synergies of 15-30%. In our base case TSRO P&L we model a tax rate of 30% so there could be synergies here as well. Two additional key swing factors which might be included in a CVR are how much expansion from PARP in other cancers and immuno-oncology…

    Ex M&A,

  • [By Ben Levisohn]

    Look out below! Shares of Tesaro (TSRO) have dropped more than 10% this afternoon after AstraZeneca (AZN) released stronger-than-expected Phase 3 trial data on a its ovarian cancer treatment.

    Agence France-Presse/Getty Images

    The Street’sAdam Feuerstein has the details on AstraZeneca’s strong data and its impact on Tesaro:

    AstraZeneca’s (AZN) PARP inhibitor Lynparza delayed the recurrence of ovarian cancer by more than two years compared to a placebo, according to results from a phase III study presented Tuesday.

    The strong benefit observed with Lynparza as ovarian cancer maintenance therapy exceeded investor expectations and bolsters AstraZeneca against a competing PARP inhibitor from Tesaro (TSRO).

    Feuerstein also notes that AstraZeneca’s data could be good newsClovis Oncology (CLVS), which also had a PARP inhibitor approved recently, if it means that its drug could work as well as Astra’s.

    In February, Leerink cut Tesaro, arguing that the rally in its shares due to a potential takeover had run too far. Will it still be a takeover target?

    Shares of Tesaro have dropped 14% to $148.01 at 3:28 p.m. today, while AstraZeneca has gained 1.1% to $30.41, and Clovis Oncology has jumped 9.8% to$66.55.

    UPDATE:Piper Jaffray’sSteven Breazzano andJoshua Schimmer note that the AstraZeneca data shows that PARPs are “more similar than different.” They explain:

    This afternoon AstraZeneca (covered by PJC analyst Richard Purkiss) reported the detailed results from the SOLO-2 maintenance study of Lynparza in 2L+ ovarian cancer. The detailed data highlights a PFS benefit of 14 months (investigator assessed, and primary endpoint) and 25 months (blinded central review) over placebo, and favorable hazard ratio of 0.30 and 0.25, respectively, confirming our view that the PARP’s are more similar than different. As such, we believe this provides a favorable readth

Top 10 Performing Stocks To Buy For 2018: Cardiome Pharma Corporation(CRME)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 30 percent to $2.72 after the company issued U.S. regulatory update for BRINAVESS. The FDA advised Cardiome that the data package proposed is not sufficient to support re-submission of the BRINAVESS NDA.

  • [By Lisa Levin]

    Shares of CARDIOME PHARMA CORP (NASDAQ: CRME) were down 43 percent to $3.01. Cardiome priced 10 million shares at $3 per share.

    Seadrill Partners LLC (NYSE: SDLP) was down, falling around 30 percent to $4.09 as the company announced plans to reduce the quarterly cash distribution to $0.10 per unit from $0.25 per unit.

Top 10 Performing Stocks To Buy For 2018: Blackrock Global(BOE)

Advisors’ Opinion:

  • [By Robert Rapier]

    Whiting Petroleum (WLL) is one of Continental’s biggest competitors in the Bakken. Whiting is the second-largest oil producer in North Dakota, averaging 82,500 barrels of oil equivalent (BOE) of production in 2012, across more than 700,000 acres of leased land.

Top 10 Performing Stocks To Buy For 2018: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).

Top 10 Performing Stocks To Buy For 2018: Clarke(t)

Advisors’ Opinion:

  • [By Jim Robertson]

    DirecTV is a direct broadcast satellite service provider and is a subsidiary of AT&T Inc (NYSE: T). Its satellite service, launched on June 17, 1994, transmits digital satellite television and audio to households in the United States, Latin America and the Caribbean withprimary competitorsbeing Dish Network and cable television providers. On July 24, 2015, after receiving approval from the FCC and United States Department of Justice, AT&T acquired DirecTV in a transaction valued at $48.5 billion. DirecTV would be paying$1.5 billion a year for the NFL Sunday Ticket.AT&T’s shares may have broken out of a downtrend:

  • [By Brian Feroldi, Dan Caplinger, Rich Duprey, Jason Hall, and Jordan Wathen]

    In order to point you in the right direction, we asked a team of Fools to highlight a dividend stock that they feel is a great stock for a beginner. Read on to see why they picked AT&T (NYSE:T),Apple (NASDAQ:AAPL),Anheuser-Busch InBev(NYSE:BUD), Mastercard(NYSE:MA), andJPMorgan Chase(NYSE:JPM).

  • [By Paul Ausick]

    AT&T Inc. (NYSE: T) dropped about 1.4% Tuesday to post a new 52-week low of $35.87 after closing Monday at $36.39. The 52-week high is $43.50. Volume was around 5.8 million shares traded, nearly 10 times the daily average of around 600,000. The company had no specific news.

  • [By Douglas A. McIntyre]

    At the other end of the iPhone 8 spectrum, wireless companies like AT&T Inc. (NYSE: T) probably will price the low-end version of the iPhone 8 below $40 a month, with 24-month contracts. This kind of price plan is a usual way for large wireless carriers to get and hold customers for long periods. Even if the carrier pays a lot for the smartphone, it presumably makes that back in monthly fees and on people who renew their subscriptions for a longer period.

  • [By Chris Lange]

    AT&T Inc.’s (NYSE: T) second-quarter results are scheduled for Tuesday. The consensus earnings estimate is $0.74 per share, on $39.82 billion in revenue. The shares were last seen at $36.51. The consensus price target is $40.27, and the 52-week trading range is $35.81 to $43.50.

Top 10 Performing Stocks To Buy For 2018: Snap-On Incorporated(SNA)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Coming up on this episode of Mad Money: Cramer interviews Nick Pinchuk, CEO of Snap-on (SNA) . Plus, don’t miss the Lightning Round. Which stocks is Cramer bullish on?

  • [By John Divine]

    Snap-on Incorporated (SNA) is my choice for the Best Stocks for 2016 competition. At a market cap of $10 billion, I doubt it will double over the next year, as some of the smaller companies in this competition might be able to.

    That said, Snap-on, which manufactures and markets hand tools and diagnostic equipment, is a rock-solid company with an attractive valuation and impressive growth. It goes for 22 times earnings, pays a consistent and modest dividend, and has been around since 1920.

    As cars get more tech-heavy and complicated, newer tools and better diagnostics will be needed — and that’s SNA’s bread ‘n’ butter. 

  • [By WWW.MONEYSHOW.COM]

    Snap-on (SNA)

    Snap-on, which is more than 100 years old, provides hand and power tools for individuals and professionals, including auto-shop tools and auto diagnostic equipment.

Top 10 Performing Stocks To Buy For 2018: PRA Group, Inc.(PRAA)

Advisors’ Opinion:

  • [By Lee Jackson]

    PRA Group Inc. (NASDAQ: PRAA) has been hit hard recently, and shareholders may be glad to know that a director took advantage of the sell-off and stepped in to buy shares. That board member bought 143,000 shares of the financial and business services company at prices that ranged from $34.40 to $34.89. The total for the buy was set at $5 million. The stock closed Friday at $32.90, in a52-week range of $21.93 to $42.70. The consensus price target is $40.60.

Top 10 Performing Stocks To Buy For 2018: Tyson Foods Inc.(TSN)

Advisors’ Opinion:

  • [By Lisa Levin] Companies Reporting Before The Bell
    Tyson Foods, Inc. (NYSE: TSN) is expected to report quarterly earnings at $1.38 per share on revenue of $9.86 billion.
    Aecom (NYSE: ACM) is projected to report quarterly earnings at $0.71 per share on revenue of $4.67 billion.
    JD.Com Inc(ADR) (NASDAQ: JD) is estimated to report quarterly earnings at $0.11 per share on revenue of $12.60 billion.
    58.com Inc (ADR) (NYSE: WUBA) is projected to report quarterly earnings at $0.28 per share on revenue of $383.60 million.
    Kamada Ltd (NASDAQ: KMDA) is expected to report quarterly earnings at $0.02 per share on revenue of $25.00 million.
    Palatin Technologies, Inc. (NYSE: PTN) is projected to report quarterly earnings at $0.06 per share on revenue of $28.00 million.
    TheStreet, Inc. (NASDAQ: TST) is estimated to report a quarterly loss at $0.02 per share on revenue of $15.81 million.
    Atlantica Yield PLC (NASDAQ: ABY) is projected to report quarterly earnings at $0.45 per share on revenue of $290.80 million.
    Asure Software Inc (NASDAQ: ASUR) is estimated to report quarterly earnings at $0.15 per share on revenue of $15.26 million.
    Cyren Ltd (NASDAQ: CYRN) is expected to report quarterly loss at $0.06 per share on revenue of $7.90 million.
    Viewray Inc (NASDAQ: VRAY) is estimated to report quarterly loss at $0.12 per share on revenue of $18.58 million.

     

  • [By Peter Graham]

    A long term performance chart shows shares ofmid cap Sanderson Farms more than doubling in value while large cap Tyson Foods, Inc (NYSE: TSN)has more than tripled in value and mid cap Pilgrim’s Pride Corporation (NASDAQ: PPC) has quadrupled in value:

  • [By Peter Graham]

    A long term performance chart shows shares of small cap Sanderson Farms doubling in value while mid cap Pilgrim’s Pride Corporation (NASDAQ: PPC) and large cap Tyson Foods, Inc (NYSE: TSN) have been even better performers albeit shares are below their peaks and have been somewhat volatile:

Top 10 Performing Stocks To Buy For 2018: Oasis Petroleum Inc.(OAS)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Oasis Petroleum Inc. (NYSE: OAS) were down 14 percent to $8.60 after the company reported a 32 million share common stock offering. The company announced Delaware Basin acquisition for $946 million and also raised its Q4 production guidance.

  • [By Jon C. Ogg]

    Oasis Petroleum Inc. (NYSE: OAS) rose a whopping 27.8% to $14.98, and the 33.2 million shares was about 2.5 times normal volume. Oasis Petroleum has a 52-week trading range of $3.40 to $15.02 and a consensus analyst price target of $14.54. The company has a total market cap of $3.5 billion.

  • [By Chris Lange]

    Oasis Petroleum Inc. (NYSE: OAS) shares slid on Tuesday after the company announced that it would be buying into the Delaware Basin. Analysts seemed to applaud this move, despite investors sending shares into the fire. Jefferies raised its price target to $14 from $13, and Morgan Stanley raised its target to $11 from $9. RBC has an Outperform rating and raised its target to $14 from $13, while SunTrust Robinson Humphrey downgraded it to Hold from Buy. Shares were down about 14% at $8.67, in a 52-week range of $6.69 to $16.73.

  • [By Paul Ausick]

    Oasis Petroleum Inc. (NYSE: OAS) is rated a Buy and the price target was lifted to $24. For 2017, the net loss estimate improved from a prior $0.27 per share to $0.23 per share. The 2018 EPS estimate rose from $0.62 to $0.64. Shares closed at $14.13 on Friday. The 52-week range is $5.93 to $14.35, and the consensus 12-month target is $17.87.

  • [By Craig Jones]

    Jon Najarian spoke on CNBC’s “Fast Money Halftime Report” about unusually high options activity in Oasis Petroleum Inc. (NYSE: OAS).

    Traders bought around 10,000 contracts of the June 10 calls in the first half of the trading session on Thursday. The trade is unusual because the average options volume in the name is a few hundred contracts. Najarian bought the calls and is planning to hold them for two weeks.

us stock market holidays

Free Preview

For full access, Log in or Subscribe Now and get 4 weeks free!

First, the definition: RMD stands for Required Minimum Distribution from a qualified retirement plan. When you contributed to an IRA you received a tax deduction. Contributions to a 401(k), 403 (b), or 457 went into the account before taxes were assessed (a pre-tax contribution). All of these plans are agreements between three parties:

us stock market holidays: BioAmber Inc.(BIOA)

Advisors’ Opinion:

  • [By Lisa Levin] Related CRMD Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher 12 Biggest Mid-Day Gainers For Tuesday CorMedix's (CRMD) CEO Khoso Baluch on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related BIOA Mid-Day Market Update: U.S. Stocks Turn Negative; AveXis Shares Spike Higher Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates BioAmber (BIOA) Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    CorMedix Inc. (NYSE: CRMD) shares fell 27.5 percent to $1.50 after the company reported Q4 results and issued a business update.
    Bioamber Inc (NYSE: BIOA) shares tumbled 23.6 percent to $2.40. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.
    The Medicines Company (NASDAQ: MDCO) shares dipped 20.9 percent to $41.62.
    Innocoll Holdings PLC (NASDAQ: INNL) shares fell 20.3 percent to $1.49. Innocoll posted a narrower-than-expected quarter loss, but revenue missed estimates. Stifel Nicolaus downgraded Innocoll from Buy to Hold.
    Rosetta Genomics Ltd. (USA) (NASDAQ: ROSG) shares declined 20.3 percent to $3.83. On Thursday, Rosetta Genomics disclosed a 1-for-12 reverse stock split.
    Esperion Therapeutics Inc (NASDAQ: ESPR) shares dropped 19.9 percent to $23.76. Esperion Therapeutics shares have jumped 106.19 percent over the past 52 weeks, while the S&P 500 index has gained 16.70 percent in the same period.
    AmTrust Financial Services Inc (NASDAQ: AFSI) tumbled 18.3 percent to $17.65. AmTrust Financial disclosed that it will delay its annual report filing for the fiscal year ended December 31, 2016.
    Qualstar Corporation (NASDAQ: QBAK) slipped 17.7 percent to $6.85. Qualstar reported a Q4 loss of $0.20 per share on revenue of $2.2 milli
  • [By Lisa Levin]

    Bioamber Inc (NYSE: BIOA) shares dropped 19 percent to $2.55. BioAmber reported FY16 adjusted loss of $1.07 per share on revenue of $8.3 million.

  • [By Paul Ausick]

    BioAmber Inc. (NYSE: BIOA) dropped nearly 29% Friday to post a new 52-week low of $2.24 after closing Thursday at $3.14. Volume of more than 1.5 million shares was about 6 times the daily average of around 240,000. The company’s annual report, filed on Thursday with its quarterly results, included a “going concern” statement from the company’s independent auditing firm.

us stock market holidays: Clean Diesel Technologies Inc.(CDTI)

Advisors’ Opinion:

  • [By Monica Gerson]

    Clean Diesel Technologies, Inc. (NASDAQ: CDTI) is projected to post a quarterly loss at $0.18 per share on revenue of $10.25 million.

    Sphere 3D Corp. (NASDAQ: ANY) is estimated to post a quarterly loss at $0.11 per share on revenue of $22.10 million.

us stock market holidays: Sears Holdings Corporation(SHLD)

Advisors’ Opinion:

  • [By Lee Jackson]

    Troubled Sears Holdings Corp. (NASDAQ: SHLD) again saw some insider buying. Fairholme Capital, a 10% owner, bought shares twice. One buy late in the week was 613,900 shares of the iconic retailer at prices that ranged from $7.89 to $9.00 apiece. The total for the trade was posted at $5 million. Earlier in the week, Fairholme bought 222,100 shares at prices between $8.75 and $8.86 a share. The total for that buy was set at $2 million. The stock closed Friday at $8.50. Its 52-week trading range is $5.50 to $19.12, and the Wall Street consensus price target is just $4.00.

  • [By Dan Caplinger]

    Yet some solid individual stock gains also helped lift investors’ moods, and Sears Holdings (NASDAQ:SHLD), National Beverage (NASDAQ:FIZZ), and JetBlue Airways (NASDAQ:JBLU) were among the best performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

  • [By Ben Levisohn]

    Sears Holdings (SHLD) reported earnings today, but don’t let its 6%-plus gain fool you. Sears is still “highly distressed,” at least according to one analyst.

    Getty Images

    Sears reported a $1.28 per share loss during the fourth quarter, smaller than the $1.70 it lost a year ago, though sales dropped to $6.05 billion, down from $7.3 billion. Cowen’s Oliver Chen and team call Sears “highly distressed.” They explain:

    Overall, SHLD remains highly distressed with significant cash constraints and will continue to close a significant number of stores and will likely continue to sell other assets to stabilize the business. We believe this presents an opportunity for other department stores and broadline retailers to continue gaining share at SHLD’s expense.

    Sears’ pain could be particularly helpful for JC Penney (JCP), Chen says:

    In our view, weakness at Sears in the home appliances and tools categories providesJC Penney an opportunity to gain share as the retailer continues to refresh its home initiatives. Recall,JC Penney already delivered positive comps in the Home division in 4Q and management is very pleased with performance with ~500 appliance showrooms which have been driving sales and gross margin dollars. We believeJC Penney has ample runway to continue driving strong performance in this department with plans to open an additional ~100 new appliance showrooms in early 2017, while continuing to add new brand partners. Furthermore, with Sears donating share,JC Penney management plans to conduct several tests within their Home Store with a focus on its home installed services program. For example,JC Penney will test an HVAC install program through its partnership with Trane and other partners.

    Shares of Sears have gained 6.1% to $7.95 at 2:23 p.m. today, while JC Penney is unchanged at $6.24.

  • [By Daniel Miller]

    It seems like Sears Holdings (NASDAQ:SHLD) has been on its death bed for some time now, and it tumbled another 20% this week setting new lows since Sears and Kmart merged roughly a decade ago. The issue facing investors this week appeared to be Sears’ liquidity. Credit-rating agency Fitch Ratings kept its speculative CC rating on the company, which suggests that a debt default is increasingly likely.

  • [By WWW.THESTREET.COM]

    Best Buy certainly has not seen the same destruction to its business like other retailers, mainly in the apparel space, have from Amazon, including Sears Holdings Corp. (SHLD) and J.C. Penney Co. Inc. (JCP) . While Best Buy’s revenue growth has been weak over the past several years, it has managed to consistently beat Wall Street profit forecasts via a combination of cost cuts and stock buybacks.

  • [By Paul Ausick]

    Sears Holdings Corp. (NASDAQ: SHLD).Between Sears and Kmart stores, the company plans 142 store closings, with more likely.

    Sports Authority.Another bankruptcy, with 140 stores closing.

us stock market holidays: PPL Corporation(PPL)

Advisors’ Opinion:

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $30.81 after closing Friday at $31.13. The 52-week high is $40.20. Volume was about 3.5 million, about 25% below the daily average of around 4.5 million shares. The electric utility company had no specific news.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) dropped about 1.7% Tuesday to post a new 52-week low of $30.44 after closing at $30.95 on Friday. Volume was around 4.1 million about 10% below the daily average of around 4.6 million. The company had no specific news.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $32.48 after closing Monday at $33.97. The 52-week high is $40.20. Volume was about 5.9 million, nearly a third higher than the daily average of around 3.9 million shares. The electric utility company had no specific news.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $30.74 after closing Tuesday at $30.76. The 52-week high is $40.20. Volume was about 3.2 million, about 25% below the daily average of around 4.5 million shares. The electric utility company had no specific news.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $31.11 after closing Wednesday at $31.59. The 52-week high is $40.20. Volume was about 9.6 million, more than double the daily average of around 4.2 million shares. The electric utility company had no specific news.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $31.53 after closing Tuesday at $32.42. The 52-week high is $40.20. Volume was about 15.5 million, more than three times the daily average of around 4 million shares. The electric utility company took a downgrade on Tuesday and the fallout continues to drop.

us stock market holidays: Atara Biotherapeutics, Inc.(ATRA)

Advisors’ Opinion:

  • [By Chris Lange]

    Atara Biotherapeutics Inc. (NASDAQ: ATRA) shares surged on Friday after the firm announced that it received clearance from the U.S. Food and Drug Administration (FDA) to initiate two Phase 3 clinical studies. Specifically these mid-stage studies deal with tabelecleucel in patients with rituximab-refractory Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative disorder (EBV+PTLD).